

Resource Summary Report

Generated by SPARC SAWG on Aug 9, 2026

FITC anti-human CD3

RRID:AB_314042

Type: Antibody

Proper Citation

BioLegend Cat# 300306, RRID:AB_314042

Antibody Information

URL: http://antibodyregistry.org/AB_314042

Proper Citation: BioLegend Cat# 300306, RRID:AB_314042

Target Antigen: CD3

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: FITC anti-human CD3

Description: This monoclonal targets CD3

Target Organism: human

Clone ID: Clone HIT3a

Antibody ID: AB_314042

Vendor: BioLegend

Catalog Number: 300306

Alternative Catalog Numbers: 300305

Record Creation Time: 20250820T001722+0000

Record Last Update: 20250820T075229+0000

Ratings and Alerts

No rating or validation information has been found for FITC anti-human CD3.

No alerts have been found for FITC anti-human CD3.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 29 mentions in open access literature.

Listed below are recent publications. The full list is available at [SPARC SAWG](#) .

Jiang W, et al. (2026) Basophil activity in atopic dermatitis: Distinct immunomodulatory roles of dupilumab and abrocitinib. The Journal of investigative dermatology.

Hu Z, et al. (2026) Extracellular ATP-P2RY2 signaling drives intratumoral prostaglandin E2 accumulation and adaptive resistance to immunotherapy in solid tumors. Immunity, 59(7), 1928.

Murdock BJ, et al. (2025) Early immune system changes in amyotrophic lateral sclerosis correlate with later disease progression. Med (New York, N.Y.), 6(8), 100673.

Pham J, et al. (2025) Nanobioreactor detection of space-associated hematopoietic stem and progenitor cell aging. Cell stem cell, 32(9), 1403.

Hu J, et al. (2025) CD169+ macrophages identify and eliminate tumor cells in colorectal cancer through CD169/CD43 interaction and FasL-driven apoptosis. Cell reports, 44(10), 116351.

Di Meo F, et al. (2025) Developing SEMA4A-directed CAR T cells to overcome low BCMA antigen density in multiple myeloma. Cancer cell, 43(12), 2298.

Pham J, et al. (2025) Space-associated stem cell hallmarks of aging and resilience in astronauts. Cell stem cell, 32(12), 1886.

Navarro P, et al. (2025) Multicenter study correlating molecular characteristics and clinical outcomes of cancer cases with patient-derived organoids. Journal of experimental & clinical cancer research : CR, 44(1), 182.

Bie L, et al. (2025) Benmelstobart plus anlotinib and chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: A phase 2 study. Cell reports. Medicine, 6(6), 102145.

Wan X, et al. (2025) Therapeutic T cells with 3-in-1 strategy for the treatment of biliary tract cancer. Cell reports. Medicine, 102349.

Wu N, et al. (2024) MerTK+ macrophages promote melanoma progression and immunotherapy resistance through AhR-ALKAL1 activation. Science advances, 10(40),

eado8366.

Shah Z, et al. (2024) Human anti-PSCA CAR macrophages possess potent antitumor activity against pancreatic cancer. *Cell stem cell*, 31(6), 803.

Vyasamneni R, et al. (2023) A universal MHCII technology platform to characterize antigen-specific CD4⁺ T_H1 cells. *Cell reports methods*, 3(1), 100388.

Crews LA, et al. (2023) Reversal of malignant ADAR1 splice isoform switching with Rebecsinib. *Cell stem cell*, 30(3), 250.

Morita R, et al. (2023) COVID-19 relapse associated with SARS-CoV-2 evasion from CD4⁺ T-cell recognition in an agammaglobulinemia patient. *iScience*, 26(5), 106685.

Wu X, et al. (2023) Multiomic landscape of immune pathogenesis in Kimura's disease. *iScience*, 26(4), 106559.

Liu X, et al. (2023) Immune checkpoint HLA-E:CD94-NKG2A mediates evasion of circulating tumor cells from NK cell surveillance. *Cancer cell*, 41(2), 272.

Imbrechts M, et al. (2022) Potent neutralizing anti-SARS-CoV-2 human antibodies cure infection with SARS-CoV-2 variants in hamster model. *iScience*, 25(8), 104705.

Sutton HJ, et al. (2021) Atypical B cells are part of an alternative lineage of B cells that participates in responses to vaccination and infection in humans. *Cell reports*, 34(6), 108684.

Mondala PK, et al. (2021) Selective antisense oligonucleotide inhibition of human IRF4 prevents malignant myeloma regeneration via cell cycle disruption. *Cell stem cell*, 28(4), 623.